Digging on BC I did not say digging in BC even if Bioniche will be in Vancouver https://www.icar2012.com/sponsors at the end of July.
I started to look at the p20 of the annual report 2011, again, to check on Urocidin competitor in detail.
#2 from p20 Eoquin is gone unless Spectrum (SPPI) finds some subset or subset of subset. Spectrum want to buy Allos (ALTH) with has a completed P2 for bladder cancer using FOLOTYN.
https://clinicaltrials.gov/ct2/show/NCT00722553?term=folotyn&rank=10. The result should come anytime but in the same time ALTH said they would not continue themself for the development due to other priorities.
https://www.sec.gov/Archives/edgar/data/1097264/000110465911060299/a11-25717_110q.htm
#3 from p20 on this list is Gemzar from Lilly(LLY). I went on https://www.gemzar.com/Pages/index.aspx but could not find anything with bladder cancer. From the Lilly website it become a little bit more complicated since they have a lot of products.
https://lilly.com/research-development/approach/Pages/clinical-development-pipeline.aspx There you can play tic-tac-toe and check if they have any bladder cancer or you can fool around and hit this:
https://www.phrma.org/medicines-development-cancer-chart you discover that it seems only 9 medicines in development. Not bad but not good enough until you get this:
https://www.phrma.org/sites/default/files/1000/phrmamedicinesindevelopmentcancer2012.pdf so let’s continue on Lilly before checking the other one. They are developing with ex Imclone a P2 https://clinicaltrials.gov/ct2/show/NCT01282463?term=IMC-18F1&rank=4. The completion is in June 2015 with a primary completion date of December 2013.
Now let’s start at the beginning, Abraxane from Celgene (CELG), P2, https://clinicaltrials.gov/ct2/show/NCT00583349?term=abraxane&rank=1
It was last verified in February. This is where you discover that companies don’t update clinicaltrials as they should do. Estimated completion date July 2012.
Aeterna Zentaris (AEZS), which has a lawsuit but as well a good news for AEZS-130. I am not sure about AEZS-108 P2 and bladder cancer, https://www.aezsinc.com/en/page.php?p=31&prod=16
It is investigated for bladder cancer.
Biocancell with a P2 completion December 2012: https://clinicaltrials.gov/ct2/show/NCT00595088?term=bc-819&rank=3
EN3488 Urocidin Bioniche Endo Health (ENDP) P3b, 80 sites with 10 withdrawn as June 26.
Genta (GNTA), first this is on otcbb with 2.6 billions shares,
.0006. https://www.otcbb.com/asp/Info_Center.asp?symbol=GNTA
I see more info on breast cancer than bladder cancer, and last update was Nov 11 with a completion date Dec 2012 on clinicaltrials.
https://clinicaltrials.gov/ct2/show/NCT01215877?term=tesetaxel&rank=5
https://www.genta.com/Products_and_Pipeline/Tesetaxel/Tesetaxel.html
The last one, a private Canadian company Viventia.
https://www.viventia.com/about.html
I could only find that on clinicaltrials https://clinicaltrials.gov/ct2/show/NCT00462488?term=VB4-845&rank=3
It was Novopharm before. Who knows were they are right now in there trials.
https://business.highbeam.com/437034/article-1G1-66306228/novopharm-biotech-inc
Are they still around?
I looked at the treatment already existing Vinflunine, Javlor from Pierre Fabre, which is the way to treat Bladder Cancer. This French article started all: https://www.prescrire.org/fr/3/31/46707/0/NewsDetails.aspx
At least you will know how much it cost, and some in English.
https://www.pharmatimes.com/Article/11-03-10/NICE_rejects_Pierre_Fabre_s_Javlor_and_Roche_s_Tarceva.aspx
In Australia as well
https://www.australianprescriber.com/magazine/34/4/119/123/new-drugs-965/Vinflunine
With an answer of Pierre Fabre Australia
https://www.australianprescriber.com/magazine/35/1/5/6
Other interesting link I hit was this one were it says: “To date, in the USA, there is no FDA-approved second-line chemotherapy for patients with metastatic bladder cancer “
https://www.ncbi.nlm.nih.gov/pubmed/21166506
Date is Jan 2011, is it still true?
#4 from p20 Iressa market by Astrazeneca and Teva.
The title is: BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer
https://clinicaltrials.gov/ct2/show/NCT00352079?term=gefitinib+bladder&rank=1
P3 Completed on January 2012. Iressa did not make it for NSCLC
#5 from p20 ihttps://clinicaltrials.gov/ct2/show/NCT01082510?term=NCT01082510&rank=1
P3 completion Dec 2019 with primary Dec 2017
Looking at this it seems that Urocidin Bioniche with Endo, if it is successful, is well placed to get the full market share since the competition either failed or is investigated and that the drugs in trials will make a late entrance in the market. Moreover there are discussions about some of the drugs on the market that are too expensive for the community with little help to the patient.
On another note if you have some time to read some books this summer, get this one:
https://www.amazon.ca/Broken-Markets-Frequency-Destroying-Confidence/dp/0132875241
Go check Stocks & Commodities p45 from the Q&A from Don Bright, this will be the new rule helping retail in Canada a little bit, another the link below:
https://www.canadiansecuritieslaw.com/2012/04/articles/securities-distribution-tradin/iiroc-proposes-changes-to-execution-and-reporting-of-offmarketplace-trades/
Remember this is only one side of Bioniche, there are 2 others, animal and food safety. So, how much is it?